





SERVICE AREA	South Carolina				
LINES OF BUSINESS (LOB)	Effective October 1, 2019 Absolute Total Care (Medicaid) Ambetter (Exchange) Effective January 11, 2021 Wellcare Prime by Absolute Total Care (Medicare-Medicaid Plan) Effective January 1,2025 ICHRA Membership Members 18 years of age and older				
	SPECIALTIES COVERAGE AUTHORIZATION				
EVOLENT ONCOLOGY MEDICATION SCOPE	<ul> <li>Gynecologic Oncology</li> <li>Hematology</li> <li>Medical Oncology</li> <li>Neurological Oncology</li> <li>Surgical Oncology</li> <li>Urology</li> <li>(Medications only)</li> </ul>	Place of Treatment: 11-Provider office 19-Outpatient off-campus 22-Outpatient on-campus 24-Ambulatory Cancer Diagnosis = C00 - D09, D37-D44, E34.0 Hematology Diagnosis = D45 - D49, D61.81, D61.82, D63.0, D63.8, D64.2-D64.3, D64.81, D64.89, D64.9, D68.59, D69.3, D69.41, D69.59, D69.6, D69.8, D69.9, D70.1-D70.9, D72.8, D72.9, D73.81, D73.9, D75.1, D75.81, D75.82 N&V=R11	Authorization required for: Infused, injectable and oral* chemotherapy, hormonal therapeutic treatment, supportive agents, and symptom management medications. *Pharmacy benefit orals and office administered (medical benefit) infused/injectable agents of the same medication type (i.e., both cancer agents) must be submitted via one combined request. Effective 08.07.2024, pharmacy benefit drugs are out of scope for the Absolute Total Care Medicaid line of business.		
AUTHORIZATION PROCESS	<ul> <li>Ordering provider's office must submit treatment requests to Evolent for prior authorization.</li> <li>Log on to the Evolent Carepro portal at <a href="https://my.newcenturyhealth.com">https://my.newcenturyhealth.com</a></li> <li>Telephonic Intake: 888.999.7713         <ul> <li>Medical Oncology - option 2</li> </ul> </li> <li>Physician Discussions: 888.999.7713         <ul> <li>Medical Oncology - option 2</li> <li>Medical Oncology - option 2, followed by option 5</li> </ul> </li> </ul>				





	HOURS OF OPERATION Monday – Friday, 5:00 AM – 5:00 PM PST (fully staffed) * Saturday, 5:00 AM – 5:00 PM PST (limited staff) * Sunday, 5:00 AM – 2:00 PM PST (limited staff) * *After hours call coverage available: Monday – Saturday, 5:00 PM PST – 5:00 AM PST* Sunday, 2:00 PM PST – 5:00 AM PST*					
	Line of Business	Part B Me	edications	Part D Medications		
		Standard	Expedite	Standard	Expedite	
EVOLENT TURNAROUND TIMES (TAT)	Absolute Total Care (Medicaid)	4 Calendar Days	24 Hours	12 Hours	12 Hours	
	Ambetter (Exchange)	1 Business Day	1 Business Day	36 Hours	12 Hours	
	Wellcare Prime (Medicare-Medicaid Plan)	36 Hours	12 Hours	36 Hours	12 Hours	
CLINICAL TRIALS	Clinical trials are out of scope for Evolent, please follow your current process.					
TRANSPLANT SERVICES	<ul> <li>Pre-Transplant: Send all chemotherapy regimen requests to Evolent for review.</li> <li>Post-Transplant: Transplant related chemotherapy authorizations requests within 1-year post-transplant should be sent to the health plan for review.</li> </ul>					
RETRO AUTHORIZATIONS	Retrospective authorizations are out of scope for Evolent. Please follow the health plan's policies and procedures.					
EVOLENT PROVIDER SOLUTIONS	Please contact your dedicated Sr. Provider Solutions Manager with any questions or to request Evolent in-service/training: Name: Claudia Prinstein-Hasbun Email: <u>chasbun@evolent.com</u> Phone: 1.571.832.0659					
EVOLENT RESOURCES	<ul> <li>Resources available under "Useful Tool/Useful Documents" in Evolent's Carepro portal:</li> <li>Clinical Data Elements: A resource tool to assist with answering the clinical questions presented during the prior authorization process.</li> <li>Dose Optimization: As per the Hematology/Oncology Pharmacy Association (HOPA), rounding of biologic and cytotoxic agents within 10% of the standard dose is designated as acceptable for routine clinical care in both the curative and incurable settings; and changes less than or equal to 10% are not expected to reduce the safety or effectiveness of therapy. Evolent offers dose rounding for many chemotherapy drugs and encourages you to take advantage of the dose rounding opportunity by accepting the calculated dose. Neither accepting nor overriding the</li> </ul>					







	<ul> <li>dose-rounded calculation has any impact on your authorization's potential for auto-approval.</li> <li>Evolent Level 1 Pathways: <u>http://pathways.newcenturyhealth.com</u>. <i>Please share this link with your pharmacy and clinical team.</i></li> <li>Oncology Supporting Documentation Grid (SDG)</li> </ul>
EVOLENT CLINICAL LEADERSHIP	Andrew Hertler, MD, FACP   Chief Medical Officer Juhee Sidhu   Vice President of Oncology Hugh Wallace, MD   Sr. Medical Director Stanley Rubin, MD   Sr. Medical Director
EXCLUSIONS	<ul> <li>Antibiotics</li> <li>Bone marrow, and stem cell transplants and CAR-T cell therapy</li> <li>Clinical trials</li> <li>CKD/ESRD patients/medications</li> <li>Controlled substances (i.e. Morphine)</li> <li>Diagnostic imaging</li> <li>Equipment requests (infusion pumps)</li> <li>Hemophilia drugs</li> <li>Inpatient radiation and chemotherapy treatments</li> <li>Non-par providers/members outside of service area</li> <li>Pharmacy benefit drugs (Effective 08.07.2024 for ATC Medicaid)</li> <li>Radiopharmaceuticals</li> <li>Soliris (J1300-Eculizumib) / Ultomiris</li> <li>Specialties, diagnoses, j-codes, CPT codes, places of treatment, and lines of business outside defined scope</li> <li>Surgeries/surgical procedures</li> </ul>